List of Radicava Ors drug patents

Radicava Ors is owned by Mitsubishi Tanabe.

Radicava Ors contains Edaravone.

Radicava Ors has a total of 3 drug patents out of which 0 drug patents have expired.

Radicava Ors was authorised for market use on 12 May, 2022.

Radicava Ors is available in suspension;oral dosage forms.

Radicava Ors can be used as treatment of amyotrophic lateral sclerosis.

The generics of Radicava Ors are possible to be released after 01 November, 2039.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11241416 MITSUBISHI TANABE Edaravone suspension for oral administration
Nov, 2039

(16 years from now)

US10987341 MITSUBISHI TANABE Edaravone suspension for oral administration
Nov, 2039

(16 years from now)

US11478450 MITSUBISHI TANABE Edaravone suspension for oral administration
Nov, 2039

(16 years from now)

Do you want to check out RADICAVA ORS patents from before 2022?
Exclusivity Exclusivity Expiration
New Product (NP) May 12, 2025

Drugs and Companies using EDARAVONE ingredient

Market Authorisation Date: 12 May, 2022

Treatment: Treatment of amyotrophic lateral sclerosis

Dosage: SUSPENSION;ORAL

More Information on Dosage

RADICAVA ORS family patents

4

United States

3

Japan

1

Korea, Republic of

1

China

1

Philippines

1

Israel

1

Brazil

1

Taiwan

1

Singapore

1

Argentina

1

Australia

1

European Union

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in